Can you please release relevant financial statements?

Financials will be released when Form C is officially filed by the team at Wefunder. Will let you know as soon as we are able. Thanks!

what kind of data you have on vascular accident ?

Richard, We do not have any clinical data yet, we are fund raising so that we can do imaging on animal models of vascular accident /human studies. Traditional CT has the scatter interference problem, typically ~5% or a lot more, sometimes 20%, or in some cases, 65% or higher SPR ( scatter to primary x ray ratio) this is with antiscatter grid and collimator ( Fig.6-9 https://www.tandfonline.com/doi/full/10.1080/00223131.2016.1236709). Please keep in mind that a 3D reconstruction require hundre...

With a companies like Nanox and Butterfly (“medtech moonshot” comps) both trading at only ~$400m enterprise value… What is the basis behind a $200m mark this early on? Both are are much further along re production capacity / FDA and have a strong B/S and big backers.

Would like to ask you or anyone in the future who is going to post here in COMPANY FAQ to 1. Share your real identity. 2. Make sure when there is a question, the data presented in the content of the question are facts and verified before posting. Thank you and regards Ying

Hello, do you have a working prototype, how does your technology compare or contrast to Nanox & Butterfly Network & do you have any direct competitors? . Hello Ying, thank you for answering my questions. Your instincts are correct. You gave me info I wanted. The analog...

Hi, John, Thanks for asking. We will disclose exactly where we are regarding the prototype stage, ( typically there are alpha, beta and pilot prototypes ), once there is NDA signed if you are interested. we aim to submit to FDA at the end of year ( estimate) . This is a public forum, and this is a IP sensitive product / technology. Hope that you understand. Direct competitors: we are in the area of x -ray / CT imaging, so any manufacturer of such device is a potential competitor. Analogy woul...

Is it fair to say that your valuation is based, in part, on your patent portfolio? If so, can you share more regarding your awarded patent and filed applications? I understand this is sensitive information to share in a public forum. 1) For your awarded patent, who is the owne...

Hi, Jason. Thank you for asking. Correct, part of the valuation is based on patent portfolio. The other parts are the know how and product engineering, team ( it is not a small effort to pull together a team of people who share the same vision and value, and focused on making the company a success), and trademarks which we have "Meta", "X" ( all filed prior to facebook changed to Meta; Binance, its cryto market place as "X-meta", and first crypto coin named "Meta I", Twitter ( Elon Musk) now ...

XENSE Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

1

Platform Imaging Technology - Planning to Disrupt the $18B Medical Imaging Industry.

2

Minimize Time to Diagnosis, Treatment & Wellness

3

X-ray: the Most Adopted Diagnostic & Intervention Imaging Modality & Central to Healthcare Delivery.

4

IMAGE LESS. LIVE BETTER!

5

Join the XENSE Investor Family to Bring uTomo / Meta CT Faster to Your Nearest clinic.

6

Our A+ Team & Investors are Experienced & Passionate 40+ Members Who Share the Same Vision & Values.

7

Large Patent Portfolio: 50+, First One Filed Has Already Been Granted by the US Patent Office.

XENSE

First Meta CT in the World, Transforming Healthcare Delivery

$187,489

Highlights

Team

Our Pitch

XENSE

Quick facts

Team profiles

Featured investor profiles

$187,489

Highlights

Related company links

Team

Our Pitch